Key Principles and Recommended Regimens for First-line Antiretroviral Therapy
Summary
- The double-blind phase III Study 102 compared cobicistat/elvitegravir/emtricitabine/tenofovir DF with efavirenz/emtricitabine/tenofovir DF in 700 treatment-naive patients[Sax 2012]
- The elvitegravir/cobicistat regimen was noninferior to the efavirenz regimen at Week 48 with 84% of the efavirenz arm vs 88% of the elvitegravir/cobicistat arm achieving virologic suppression to HIV-1 RNA < 50 copies/mL by US FDA snapshot analysis
- Noninferiority has been documented through Week 144[Wohl 2014]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Initial Antiretroviral Therapy